Genedrive (GB:GDR) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Genedrive PLC has received the coveted FDA Breakthrough Device Designation for its Genedrive MT-RNR1 ID Kit, the first rapid point-of-care test to help prevent aminoglycoside-induced hearing loss in infants. This pioneering test, which identifies genetic variants linked to hearing loss, aims to improve patient outcomes and reduce healthcare costs by avoiding expensive malpractice litigation. The designation expedites the device’s development and review, potentially speeding up its entry into the lucrative U.S. market.
For further insights into GB:GDR stock, check out TipRanks’ Stock Analysis page.